文献速递细菌感染、耐药与抗菌药物医院感染防控

加拿大医院耐甲氧西林金黄色葡萄球菌17年特征分析(CANWARD研究2007-2023)

Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007-23).
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

该研究回顾了2007至2023年加拿大三级医院住院和门诊患者MRSA分离株的人群参数、分子特征和体外药敏结果。共鉴定2697株MRSA,年比例从2007年26.1%降至2017年16.0%后回升至2023年24.2%,社区相关型 spa 型别从20.8%增至75.0%,万古霉素等药物敏感率≥99%。

要点

  • MRSA年比例呈先降后升趋势,2023年回升至24.2%。
  • 社区相关MRSA spa型别占比从20.8%升至75.0%,医院相关型相应下降。
  • 万古霉素、利奈唑胺、达托霉素等敏感率≥99%,克林霉素敏感率在HA-MRSA与CA-MRSA间差异显著。

核心结论

  • 加拿大医院MRSA流行病学持续变化,需持续国家监测以支持治疗指南和感染防控。

研究设计与样本

  • CANWARD研究为2007至2023年加拿大三级医院住院和门诊患者MRSA分离株的回顾性分析。
  • 共纳入12734株金黄色葡萄球菌中的2697株MRSA,采用DNA测序进行spa分型、PCR检测PVL基因,并按CLSI M7第12版进行肉汤微量稀释药敏试验,MIC按CLSI M100第34版判读。

主要发现

  • MRSA年比例从2007年26.1%显著降至2017年16.0%,后回升至2023年24.2%(P<0.0001)。
  • CA-MRSA spa型别从2007年20.8%增至2023年75.0%,HA-MRSA从79.2%降至25.0%(P<0.0001)。
  • 所有MRSA中主要spa型别为t002(36.3%,HA-MRSA基因型)和t008(24.5%,CA-MRSA基因型)。
  • PVL检出率为所有MRSA的36.0%,其中CA-MRSA为76.3%,HA-MRSA为2.7%。
  • 所有MRSA对头孢比罗、达巴万星、达托霉素、利奈唑胺、呋喃妥因和万古霉素的敏感率≥99%。

关键数值与推荐

  • 克林霉素敏感率:HA-MRSA 38.9%,CA-MRSA 86.9%(P<0.0001)。
  • 甲氧苄啶/磺胺甲噁唑敏感率:HA-MRSA 91.4%,CA-MRSA 98.8%(P<0.0001)。
  • 多西环素敏感率:HA-MRSA 96.6%,CA-MRSA 98.8%(P=0.0003)。

临床怎么用

  • 经验性治疗MRSA感染时可优先考虑万古霉素、利奈唑胺、达托霉素等敏感率≥99%的药物。
  • 克林霉素经验性用药需考虑HA-MRSA与CA-MRSA敏感率差异,必要时依据药敏结果调整。
  • 持续监测MRSA分子流行病学有助于更新治疗指南和感染控制措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study reviewed the patient demographic parameters, molecular characteristics and in vitro antimicrobial susceptibility testing results for MRSA isolates infecting inpatients and outpatients presenting for care to tertiary-care Canadian hospitals between 2007 and 2023. METHODS: DNA sequencing was used to generate spa types. Panton-Valentine leukocidin (PVL) genes were detected by PCR. Broth microdilution antimicrobial susceptibility testing (CLSI M7, 12th edition, 2024) was performed with MICs interpreted by CLSI M100 breakpoints (34th edition, 2024) when available. RESULTS: In total, 2697 MRSA were identified among 12734 Staphylococcus aureus isolates submitted to the CANWARD study between 2007 and 2023. The annual proportion of MRSA decreased significantly from 2007 (26.1%) to 2017 (16.0%) and then increased to 24.2% in 2023 (P < 0.0001). From 2007 to 2023, community-associated (CA)-MRSA spa types increased from 20.8% to 75.0% (P < 0.0001), while hospital-associated (HA)-MRSA decreased from 79.2% to 25.0% (P < 0.0001). The predominant MRSA spa types identified among all isolates were t002 (36.3%), an HA-MRSA genotype, and t008 (24.5%), a CA-MRSA genotype. PVL was detected in 36.0% of all MRSA isolates (76.3% of CA-MRSA; 2.7% of HA-MRSA). Percent susceptible values for all MRSA isolates were ≥99% for ceftobiprole, dalbavancin, daptomycin, linezolid, nitrofurantoin and vancomycin. Notable differences in percent susceptible values were identified for clindamycin (HA-MRSA, 38.9%; CA-MRSA, 86.9%) (P < 0.0001) trimethoprim/sulfamethoxazole (HA-MRSA, 91.4%; CA-MRSA, 98.8%) (P < 0.0001) and doxycycline (HA-MRSA, 96.6%; CA-MRSA, 98.8%) (P = 0.0003). CONCLUSIONS: The changing epidemiology of MRSA in Canadian hospitals warrants continued national surveillance efforts as a resource to support therapeutic guidelines and infection control and prevention programmes.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Brahami A, Karlowsky JA, McCracken M, et al. Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007-23). J Antimicrob Chemother. 2025. PMID: 40873028. doi:10.1093/jac/dkaf218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。